[go: up one dir, main page]

WO1997007819B1 - Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter - Google Patents

Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter

Info

Publication number
WO1997007819B1
WO1997007819B1 PCT/EP1996/003733 EP9603733W WO9707819B1 WO 1997007819 B1 WO1997007819 B1 WO 1997007819B1 EP 9603733 W EP9603733 W EP 9603733W WO 9707819 B1 WO9707819 B1 WO 9707819B1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
antigen
receptor
pharmaceutical composition
Prior art date
Application number
PCT/EP1996/003733
Other languages
German (de)
English (en)
Other versions
WO1997007819A1 (fr
Filing date
Publication date
Priority claimed from DE19531346A external-priority patent/DE19531346A1/de
Application filed filed Critical
Priority to DE59608213T priority Critical patent/DE59608213D1/de
Priority to US09/029,369 priority patent/US6294167B1/en
Priority to AT96929318T priority patent/ATE208630T1/de
Priority to DK96929318T priority patent/DK0845998T3/da
Priority to EP96929318A priority patent/EP0845998B1/fr
Publication of WO1997007819A1 publication Critical patent/WO1997007819A1/fr
Publication of WO1997007819B1 publication Critical patent/WO1997007819B1/fr

Links

Abstract

L'invention concerne des médicaments contenant des anticorps présentant au moins une spécificité, qui identifient l'antigène du MCHII d'un patient à traiter. L'invention concerne en outre des anticorps présentant deux spécificités ou plus, qui identifient l'antigène MCHII d'un patient, ainsi que des compositions diagnostiques contenant lesdits anticorps.
PCT/EP1996/003733 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter WO1997007819A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE59608213T DE59608213D1 (de) 1995-08-25 1996-08-23 Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
US09/029,369 US6294167B1 (en) 1995-08-25 1996-08-23 Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated
AT96929318T ATE208630T1 (de) 1995-08-25 1996-08-23 Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
DK96929318T DK0845998T3 (da) 1995-08-25 1996-08-23 Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
EP96929318A EP0845998B1 (fr) 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19531346.1 1995-08-25
DE19531346A DE19531346A1 (de) 1995-08-25 1995-08-25 Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen

Publications (2)

Publication Number Publication Date
WO1997007819A1 WO1997007819A1 (fr) 1997-03-06
WO1997007819B1 true WO1997007819B1 (fr) 1997-05-15

Family

ID=7770409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003733 WO1997007819A1 (fr) 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter

Country Status (8)

Country Link
US (1) US6294167B1 (fr)
EP (1) EP0845998B1 (fr)
AT (1) ATE208630T1 (fr)
DE (2) DE19531346A1 (fr)
DK (1) DK0845998T3 (fr)
ES (1) ES2164914T3 (fr)
PT (1) PT845998E (fr)
WO (1) WO1997007819A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002567A2 (fr) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions et procedes destines a des homoconjugues d'anticorps qui induisent l'arret de la croissance ou l'apoptose de cellules tumorales
DE19937264A1 (de) * 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
CA2391925A1 (fr) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Anticorps
US20030082188A1 (en) * 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
GB0509318D0 (en) * 2005-05-06 2005-06-15 Chiron Srl TCR-independent activation of T cells
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
EP1820513A1 (fr) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
US7862813B2 (en) * 2006-07-29 2011-01-04 Bjork Jr Robert Lamar Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
EP2241576A1 (fr) 2009-04-17 2010-10-20 Trion Pharma Gmbh Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+
SMT202100231T1 (it) * 2014-03-13 2021-05-07 Univ Basel Ligandi di carboidrato che si legano ad anticorpi igm contro glicoproteina associata a mielina
BR112019010878A2 (pt) 2016-11-29 2019-10-01 Lindhofer Horst combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos
CA3221995C (fr) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Proteines de fixation multi-specifiques destinees a l'activation de cellules tueuses naturelles et leurs utilisations therapeutiques pour traiter le cancer
WO2018152518A1 (fr) 2017-02-20 2018-08-23 Adimab, Llc Protéines se liant à her2, nkg2d et cd16
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
ES2986967T3 (es) 2018-02-08 2024-11-13 Dragonfly Therapeutics Inc Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
EP3755721A4 (fr) 2018-02-20 2021-12-22 Dragonfly Therapeutics, Inc. Protéines de liaison multi-spécifiques qui se lient à cd33, nkg2d et cd16, et procédés d'utilisation
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
BR112021002072A2 (pt) 2018-08-08 2021-06-01 Dragonfly Therapeutics, Inc. proteínas de ligação multiespecíficas que se ligam a bcma, nkg2d e cd16, e métodos de uso
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2022187539A1 (fr) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Méthodes de traitement du cancer à l'aide de protéines de liaison multi-spécifiques qui se lient à nkg2d, à cd16 et à un antigène associé à une tumeur

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies

Similar Documents

Publication Publication Date Title
WO1997007819B1 (fr) Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter
Mason et al. LGL-1: a non-polymorphic antigen expressed on a major population of mouse natural killer cells.
Ciccone et al. Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells
Reinherz et al. Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes
Weiss et al. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line.
US6294167B1 (en) Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated
Bonnefoy et al. The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens.
US5777084A (en) Antibody BV10A4H2 specific for human FLT3/FLK2 receptor and mybridoma
EP0403156B1 (fr) Anticorps monoclonaux améliorés contre le récepteur alpha/bêta des cellules T humaines, leur production et leur utilisation
US5885573A (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FI117900B (fi) Menetelmä solun valmistamiseksi, joka ilmentää soluvälitteisen immuuniteetin uudelleensuuntaavia reseptorikimeeroja, ja niitä koodaava DNA ja vektori
Schiller et al. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells
Spertini et al. Induction of human T cell proliferation by a monoclonal antibody to CD5.
Pauza et al. Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains.
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
AU1583595A (en) T-cell antigens, and their use in diagnosis and treatment of t-cell mediated conditions
JPH0223156B2 (fr)
EP0241811B1 (fr) Anticorps monoclonal contre le récepteur de l'interleukine-2 humaine
FI75598C (fi) Foerfarande foer framstaellning av en monoklonal antikropp mot en maensklig tymocytantigen medelst en ny hybridcellinje.
Dang et al. FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation
Alvarez-Vallina et al. Delimitation of the proliferative stages in the human thymus indicates that cell expansion occurs before the expression of CD3 (T cell receptor)
Braakman et al. Expression of CD45 isoforms by fresh and activated human γδ T lymphocytes and natural killer cells
US6156882A (en) Antibody 4G8B4B12
Lobo et al. Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells.
US7279291B2 (en) Polypeptides having a triggering NK activity and biological applications